PDSB Valuation
PDS Biotechnology Corp
$
1.240
- Overview
- Forecast
- Valuation
- Earnings
PDSB Relative Valuation
PDSB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PDSB is overvalued; if below, it's undervalued.
Historical Valuation
PDS Biotechnology Corp (PDSB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.91. The fair price of PDS Biotechnology Corp (PDSB) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.24
Fair
-1.62
PE
1Y
3Y
5Y
Trailing
Forward
-1.00
EV/EBITDA
PDS Biotechnology Corp. (PDSB) has a current EV/EBITDA of -1.00. The 5-year average EV/EBITDA is -3.57. The thresholds are as follows: Strongly Undervalued below -11.07, Undervalued between -11.07 and -7.32, Fairly Valued between 0.18 and -7.32, Overvalued between 0.18 and 3.93, and Strongly Overvalued above 3.93. The current Forward EV/EBITDA of -1.00 falls within the Historic Trend Line -Fairly Valued range.
-1.17
EV/EBIT
PDS Biotechnology Corp. (PDSB) has a current EV/EBIT of -1.17. The 5-year average EV/EBIT is -3.35. The thresholds are as follows: Strongly Undervalued below -9.74, Undervalued between -9.74 and -6.55, Fairly Valued between -0.16 and -6.55, Overvalued between -0.16 and 3.03, and Strongly Overvalued above 3.03. The current Forward EV/EBIT of -1.17 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
PDS Biotechnology Corp. (PDSB) has a current PS of 0.00. The 5-year average PS is 86.16. The thresholds are as follows: Strongly Undervalued below -665.96, Undervalued between -665.96 and -289.90, Fairly Valued between 462.23 and -289.90, Overvalued between 462.23 and 838.29, and Strongly Overvalued above 838.29. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
PDS Biotechnology Corp. (PDSB) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.81. The thresholds are as follows: Strongly Undervalued below -12.47, Undervalued between -12.47 and -8.64, Fairly Valued between -0.98 and -8.64, Overvalued between -0.98 and 2.86, and Strongly Overvalued above 2.86. The current Forward P/OCF of 0.00 falls within the Overvalued range.
-1.58
P/FCF
PDS Biotechnology Corp. (PDSB) has a current P/FCF of -1.58. The 5-year average P/FCF is -1.99. The thresholds are as follows: Strongly Undervalued below -5.60, Undervalued between -5.60 and -3.79, Fairly Valued between -0.19 and -3.79, Overvalued between -0.19 and 1.61, and Strongly Overvalued above 1.61. The current Forward P/FCF of -1.58 falls within the Historic Trend Line -Fairly Valued range.
PDS Biotechnology Corp (PDSB) has a current Price-to-Book (P/B) ratio of 3.62. Compared to its 3-year average P/B ratio of 4.27 , the current P/B ratio is approximately -15.10% higher. Relative to its 5-year average P/B ratio of 4.00, the current P/B ratio is about -9.48% higher. PDS Biotechnology Corp (PDSB) has a Forward Free Cash Flow (FCF) yield of approximately -59.43%. Compared to its 3-year average FCF yield of -29.78%, the current FCF yield is approximately 99.58% lower. Relative to its 5-year average FCF yield of -22.88% , the current FCF yield is about 159.73% lower.
3.62
P/B
Median3y
4.27
Median5y
4.00
-59.43
FCF Yield
Median3y
-29.78
Median5y
-22.88
Competitors Valuation Multiple
The average P/S ratio for PDSB's competitors is 9.72, providing a benchmark for relative valuation. PDS Biotechnology Corp Corp (PDSB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PDSB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PDSB in the past 1 year is driven by Unknown.
People Also Watch
SWVL
Swvl Holdings Corp
3.490
USD
+2.35%
XPL
Solitario Resources Corp
0.766
USD
-0.52%
EMCG
Embrace Change Acquisition Corp
0
USD
-9.18%
HYMC
Hycroft Mining Holding Corporation
4.550
USD
+7.31%
GEG
Great Elm Group Inc
2.410
USD
-4.17%
STTK
Shattuck Labs Inc
0.981
USD
-1.21%
RPID
Rapid Micro Biosystems Inc
2.410
USD
-3.98%
NTZ
Natuzzi SpA
3.070
USD
+3.65%
FAQ
Is PDS Biotechnology Corp (PDSB) currently overvalued or undervalued?
PDS Biotechnology Corp (PDSB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.91. The fair price of PDS Biotechnology Corp (PDSB) is between NaN to NaN according to relative valuation methord.
What is PDS Biotechnology Corp (PDSB) fair value?
How does PDSB's valuation metrics compare to the industry average?
What is the current P/B ratio for PDS Biotechnology Corp (PDSB) as of Sep 01 2025?
What is the current FCF Yield for PDS Biotechnology Corp (PDSB) as of Sep 01 2025?
What is the current Forward P/E ratio for PDS Biotechnology Corp (PDSB) as of Sep 01 2025?